Extracellular Vesicles: Translational Agenda Questions for Three Protozoan Parasites

Kwesi Z. Tandoh,Ana Victoria Ibarra‐Meneses,David Langlais,Martin Olivier,Ana Claudia Torrecilhas,Christopher Fernandez‐Prada,Neta Regev‐Rudzki,Nancy O. Duah‐Quashie,Kwesi Z. Tandoh,Ana Victoria Ibarra‐Meneses,Ana Claudia Torrecilhas,Nancy O. Duah‐Quashie
DOI: https://doi.org/10.1111/tra.12935
2024-04-19
Traffic
Abstract:The framework summarises the potential translational utilities of extracellular vesicles in Plasmodium falciparum, Leishmania spp. and Trypanosoma cruzi. It highlights three strategic questions to be interrogated to usher in a translational future. TR1, translational agenda 1; TR2, translational agenda 2; TR3, translational agenda 3; CD, Chagas disease. The protozoan parasites Plasmodium falciparum, Leishmania spp. and Trypanosoma cruzi continue to exert a significant toll on the disease landscape of the human population in sub‐Saharan Africa and Latin America. Control measures have helped reduce the burden of their respective diseases—malaria, leishmaniasis and Chagas disease—in endemic regions. However, the need for new drugs, innovative vaccination strategies and molecular markers of disease severity and outcomes has emerged because of developing antimicrobial drug resistance, comparatively inadequate or absent vaccines, and a lack of trustworthy markers of morbid outcomes. Extracellular vesicles (EVs) have been widely reported to play a role in the biology and pathogenicity of P. falciparum, Leishmania spp. and T. cruzi ever since they were discovered. EVs are secreted by a yet to be fully understood mechanism in protozoans into the extracellular milieu and carry a cargo of diverse molecules that reflect the originator cell's metabolic state. Although our understanding of the biogenesis and function of EVs continues to deepen, the question of how EVs in P. falciparum, Leishmania spp. and T. cruzi can serve as targets for a translational agenda into clinical and public health interventions is yet to be fully explored. Here, as a consortium of protozoan researchers, we outline a plan for future researchers and pose three questions to direct an EV's translational agenda in P. falciparum, Leishmania spp. and T. cruzi. We opine that in the long term, executing this blueprint will help bridge the current unmet needs of these medically important protozoan diseases in sub‐Saharan Africa and Latin America.
cell biology
What problem does this paper attempt to address?